HELA
About the company
Hela RadioPharma is establishing the Nordic region’s first modern large-scale isotope production facility, with early access to Sumitomo’s high-yield MP-30X cyclotron. The facility will produce At-211, Cu-64, Zr-89 and other critical isotopes at high volume and quality, securing supply for cancer diagnostics and targeted alpha therapy (TAT). By combining strategic partnerships with universities and hospitals (e.g. Karolinska Institute) and a landlord-financed, purpose-built facility next to Karolinska University Hospital, Hela ensures reliable domestic production. This positions Hela as a first-mover in Northern Europe’s isotope market, addressing an urgent global shortage that today delays clinical trials, hinders next-gen therapies, and slows commercialization.
Quick links:
Contact:
Liliane Rothoff, Managing Director
Email: l.rothoff@helaradiopharma.com
Phone: +46 760 08 41 80
Capital need and valuation:
Capital Need: €7 million (2025 financing round)
Pre-Money Valuation: Startup stage – valuation to be confirmed
Use of Funds
Equipment lease, facility completion with Hemsö, CMO set-up, staff, and operational ramp-up
Financial forecast
Estimated Turnover 2026: Revenue start 2027
Revenue Model: Direct isotope sales to hospitals and research institutions; CMO (contract manufacturing) for pharma; long-term supply contracts
Previous investments
Founders have invested: €500 000
External investors: €1 million seed round completed 2024/2025
Vision and impact
Hela’s vision is to secure Northern Europe’s preparedness in isotope supply and position Sweden as a European hub for radiopharmaceutical innovation. By enabling precision cancer care through Theranostics, Hela directly contributes to UN SDG 3 (Good Health & Well-Being). Long term, Hela will scale to additional services as a CDMO, reinforcing Europe’s autonomy in critical healthcare infrastructure.
Risk management
Risks: Technology integration, regulatory approval, isotope market volatility, high capital intensity
Mitigation:
- Exclusive Sumitomo MP-30X technology access
- Long-term facility financing by Hemsö (AP3-backed landlord)
- Strategic collaborations with Karolinska Institute and Gothenburg University
- Compliance with GMP standards